## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.8% in lower entry zone (4.0-10.0%), top 5% cross-sectional ranking. Short-term MRS_5 (2.4%) confirms momentum alignment. Strong momentum (+3.4% 5-day acceleration). Outperforming sector by 4.1%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($39.40)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 2)

**1. Centene (CNC): Buy, Sell, or Hold Post Q3 Earnings?**
- Source: Finviz | 20260101T230500 | Bearish | Relevance: 100%
- Despite Centene's 22% return over the past six months and its stock price reaching $41.20, an analysis suggests it's not an attractive buying opportunity. Reasons include a plateauing customer base, declining EPS over the last five years, and decreasing return on invested capital (ROIC). While the valuation is reasonable at 17.7x forward P/E, the underlying shaky fundamentals present too much downside risk.

**2. Ninety One UK Ltd Takes $23.38 Million Position in Centene Corporation $CNC**
- Source: MarketBeat | 20260102T111654 | Neutral | Relevance: 100%
- Ninety One UK Ltd has acquired a new stake in Centene Corporation (NYSE:CNC) valued at $23.38 million, representing 0.13% of the company. Centene reported a Q3 beat with $0.50 EPS and revenue up 18.2% year-over-year, despite a negative net margin. Analysts currently rate Centene as "Hold" with an average price target of $38.44.

**3. Centene Corp. stock: Managed?care quiet climber with cautious gains and a watchful Wall Street**
- Source: AD HOC NEWS | 20260101T200209 | Somewhat-Bullish | Relevance: 100%
- Centene Corp. stock, a managed-care provider, has shown cautious gains over the past three months, driven by steady buying in thin holiday trading. Despite no explosive recent headlines, its consistent upward momentum and positive analyst coverage suggest a repricing of risk and a quiet accumulation phase among investors. Wall Street remains cautiously optimistic, citing the company's leverage to government healthcare programs and its portfolio optimization efforts as key future drivers.

**4. Ethic Inc. Purchases 35,149 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251231T094144 | Neutral | Relevance: 100%
- Ethic Inc. increased its stake in Centene Corporation (NYSE:CNC) by 51.4% during the third quarter, acquiring an additional 35,149 shares. This brings Ethic Inc.'s total holdings in Centene to 103,533 shares, valued at $3.694 million. Other institutional investors also adjusted their positions, and Wall Street analysts currently have a "Hold" rating on the stock with a consensus price target of $38.44.

**5. Three Centene health plans fined $1.7 million by state, health officials say**
- Source: The Center Square | 20251231T000904 | Bearish | Relevance: 100%
- Three Centene Corporation health plans have been fined $1.7 million by the California Department of Managed Health Care for failing to meet timely access standards for appointments. The fines were levied against Health Net ($1.2 million), Human Affairs International of California ($300,000), and Health Net Community Solutions, Inc. ($200,000). The department emphasized that timely access to care is a legal right, and the fines aim to ensure health plans comply with these standards, with funds directed toward programs supporting underserved areas and healthcare data collection.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.64 elevated, pricing in significant growth expectations. Forward P/E 14.4x attractive for 42% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.5B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.64 |
| Forward P/E | 14.4 |
| Current P/E | 20.6 |
| YoY Growth | 42.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 2.3% to 5.8% (+3.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 95th percentile. MRS_5 at 2.4% confirms short-term momentum alignment. AM_20 at 5.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.76% (CS: 95) | Strong |
| RSI_14 | 66.2 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.107x | Above |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $41.78
- **Stop Loss:** $39.40 (5.7% risk)
- **Target:** $45.35 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 605
- **Position Value:** $25,276.90
- **Portfolio %:** 25.28%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*